Page last updated: 2024-11-06

nicotinanilide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Nicotinanilide is a synthetic compound derived from nicotine and aniline. Its synthesis typically involves the reaction of nicotinic acid chloride with aniline in the presence of a base. Research into nicotinanilide is driven by its potential applications in various fields. Notably, it has shown promising activity as an insecticide, particularly against agricultural pests. This insecticidal effect is attributed to its ability to interfere with the nervous system of insects. Additionally, nicotinanilide exhibits pharmacological properties, demonstrating anti-inflammatory and analgesic effects. Its potential as a therapeutic agent, particularly in treating inflammatory conditions, is under investigation. Further research is needed to explore its safety profile and optimize its efficacy for potential therapeutic applications. However, due to its toxicity to certain organisms, its use in agriculture and medicine needs careful evaluation and consideration.'

nicotinanilide: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID74463
CHEMBL ID454533
SCHEMBL ID352439
MeSH IDM0117040

Synonyms (34)

Synonym
HMS1757F15
nicotinanilide
n-phenylnicotinamide
1752-96-1
pyridine-3-carboxy-anilide
nsc-108206
nsc108206
3-pyridinecarboxamide, n-phenyl-
nicotinanilide, 97%
OPREA1_545261
inchi=1/c12h10n2o/c15-12(10-5-4-8-13-9-10)14-11-6-2-1-3-7-11/h1-9h,(h,14,15
n-phenylpyridine-3-carboxamide
CHEMBL454533
AKOS001025636
einecs 217-138-4
nsc 108206
FT-0603574
0on ,
n-phenyl-3-pyridinecarboxamide
nicotinic anilide
SCHEMBL352439
4EH6
MB00323
4G-346S
DTXSID10169950
mfcd00023572
SR-01000389183-1
sr-01000389183
J-011106
F12013
3-pyridinecarboxamide,n-phenyl-
Q27451286
pyridine-3-carboxanilide
Z27782625

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Herein, the discovery and optimization of a novel series of 2,5-diarylnicotinamides as potent and orally bioavailable orexin-2 receptor selective antagonists is described."( Discovery of 2,5-diarylnicotinamides as selective orexin-2 receptor antagonists (2-SORAs).
Bednar, RA; Bruno, JG; Cabalu, TD; Coleman, PJ; Cui, D; Garson, S; Hartman, GD; Lemaire, W; Meacham Harrell, C; Mercer, SP; Murphy, KL; Prueksaritanont, T; Reiss, DR; Renger, JJ; Roecker, AJ; Tang, C; Winrow, CJ; Young, SD, 2013
)
0.39

Dosage Studied

ExcerptRelevanceReference
"4%-100% snails on moist soil were killed at over 20 degrees C, exposed to spraying dosage of 1-2 g/m2 for 1-3 days."( [Evaluation of molluscicidal effect of nicotinanilide against Oncomelania snails].
Chan, HL; Chen, ZP; Hua, DS; Shen, BR; Tao, HQ, 1991
)
0.55
" A compound from this series demonstrated potent sleep promotion when dosed orally to EEG telemetrized rats."( Discovery of 2,5-diarylnicotinamides as selective orexin-2 receptor antagonists (2-SORAs).
Bednar, RA; Bruno, JG; Cabalu, TD; Coleman, PJ; Cui, D; Garson, S; Hartman, GD; Lemaire, W; Meacham Harrell, C; Mercer, SP; Murphy, KL; Prueksaritanont, T; Reiss, DR; Renger, JJ; Roecker, AJ; Tang, C; Winrow, CJ; Young, SD, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (9)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Mitogen-activated protein kinase 14Homo sapiens (human)IC50 (µMol)3,471.0000292.00001,327.00003,471.0000AID977608
Chain A, Mitogen-activated protein kinase 14Homo sapiens (human)IC50 (µMol)3,471.0000292.00001,327.00003,471.0000AID977608
Chain A, Mitogen-activated protein kinase 14Homo sapiens (human)IC50 (µMol)3,471.0000292.00001,327.00003,471.0000AID977608
Chain A, Mitogen-activated protein kinase 14Homo sapiens (human)IC50 (µMol)3,471.0000292.00001,327.00003,471.0000AID977608
Chain A, Mitogen-activated protein kinase 14Homo sapiens (human)IC50 (µMol)3,471.0000292.00001,327.00003,471.0000AID977608
Chain A, Mitogen-activated protein kinase 14Homo sapiens (human)IC50 (µMol)3,471.0000292.00001,327.00003,471.0000AID977608
Chain A, Mitogen-activated protein kinase 14Homo sapiens (human)IC50 (µMol)3,471.0000292.00001,327.00003,471.0000AID977608
Chain A, Mitogen-activated protein kinase 14Homo sapiens (human)IC50 (µMol)3,471.0000292.00001,327.00003,471.0000AID977608
Chain A, Mitogen-activated protein kinase 14Homo sapiens (human)IC50 (µMol)3,471.0000292.00001,327.00003,471.0000AID977608
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID409603Inhibition of human aquaporin 4 M23 isoform expressed in Xenopus laevis oocytes at 20 uM2009Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1
Identification of aquaporin 4 inhibitors using in vitro and in silico methods.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2013Nature chemistry, Jan, Volume: 5, Issue:1
Natural-product-derived fragments for fragment-based ligand discovery.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (7.69)18.7374
1990's2 (15.38)18.2507
2000's4 (30.77)29.6817
2010's6 (46.15)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.40

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.40 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.86 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.40)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]